Integra LifeSciences extends $150 million receivables facility to April 10, 2029
Integra LifeSciences amended its $150 million accounts receivable securitization facility on April 10, 2026, extending its scheduled termination date to April 10, 2029. The amendments also update customary representations, covenants and receivables concentration limits, and the filing describes them as customary terms.
Key points
- Facility size is $150 million, originally entered into December 18, 2018, to reduce revolving borrowings and add liquidity.
- Amendments dated April 10, 2026 include Amendment No. 8 to the Receivables Financing Agreement and Amendment No. 1 to the Purchase and Sale Agreement.
- Scheduled termination date extended to April 10, 2029, with PNC Bank, National Association as Administrative Agent.
- Full amendment texts will be filed as exhibits to the Form 10-Q for the quarter ended March 31, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 15, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.